Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial-Reference-Cited by-同舟云学术

Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial

Published:2017-04 Issue:4 Volume:4 Page:e165-e175
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Masarova Lucia,Patel Keyur P,Newberry Kate J,Cortes Jorge,Borthakur Gautam,Konopleva Marina,Estrov Zeev,Kantarjian Hagop,Verstovsek Srdan

Publisher

Elsevier BV

Subject

Hematology

Reference32 articles.

1. Some speculations on the myeloproliferative syndromes [editorial];Dameshek;Blood,1951

2. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera;Marchioli;J Clin Oncol,2005

3. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors;Wolanskyj;Mayo Clin Proc,2006

4. Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives;Hasselbalch;Curr Drug Targets,2011

5. Recombinant interferon-alpha for treatment of polycythaemia vera;Silver;Lancet,1988

Cited by 101 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Национальные клинические рекомендации по диагностике и лечению Ph-негативных миелопролиферативных новообразований (истинной полицитемии, эссенциальной тромбоцитемии, первичного миелофиброза) (редакция 2024 г.);Clinical Oncohematology;2024-07-01

2. Polycythemia vera: past, present and future;Leukemia & Lymphoma;2024-06-13

3. Essential thrombocythaemia: A contemporary approach with new drugs on the horizon;British Journal of Haematology;2024-04-08

4. Treatment outcome and germline predictive factors of ropeginterferon alpha‐2b in myeloproliferative neoplasm patients;Cancer Medicine;2024-04

5. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options;Annals of Hematology;2024-03-04